3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026
Key PointsEven if it’s not being officially reported yet, its drug Casgevy is accruing revenue that will show up in earnest beginning next year.
Even though CRISPR Therapeutics has had a difficult few years, it remains an attractive option for investors who are willing to take on the associated risks. The company's potential, despite its speculative nature and volatility, makes it a promising investment. Here are three key reasons why CRISPR Therapeutics stock is still worth considering.
First, the company is still in the early stages of its AI-driven research and development (Act 1), with the global rollout (Act 2) yet to come. While most investors may have missed the AI boat in 2005 by not buying Nvidia, CRISPR Therapeutics is only at the beginning of its R&D phase. Once the global rollout of gene therapies begins, the company's stock could experience significant growth.
Second, CRISPR Therapeutics has already made a significant breakthrough with the FDA approval of Casgevy, a gene editing drug for sickle cell disease. This pioneering achievement has set a high standard for the company, which was co-founded by Nobel Prize-winning geneticist Dr. Emmanuelle Charpentier. The success of Casgevy has provided a strong foundation for the company's future growth.
Third, CRISPR Therapeutics has a diverse pipeline of clinical trials and potential drug development opportunities. The company is currently conducting trials for oncology drugs, cardiovascular treatments, and cholesterol-lowering therapies. For example, its CTX310 therapy has shown promising results in reducing the ANGPTL3 protein, which interferes with fat-reducing enzymes.
Additionally, CTX611 is demonstrating strong efficacy in treating thromboembolic and cardiovascular conditions. These ongoing trials and potential drug developments could rejuvenate investor interest in the company's growth prospects.
With a well-established CRISPR/Cas9 gene-editing platform, CRISPR Therapeutics has nearly limitless possibilities for drug development. The global CRISPR-based gene-editing drug market is expected to grow at an annual rate of 12.9% through 2035, reaching nearly $15 billion. Given its co-founder's Nobel Prize-winning work, CRISPR Therapeutics is well-positioned to capture a significant share of this market growth.
Furthermore, the company could also be an attractive acquisition target for other biotechnology firms, which adds to its investment appeal.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
